Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Solabegron · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Solabegron | DRUG | - |
| solabegron and oxybutynin | DRUG | - |
| Placebo | DRUG | - |
| Solabegron (GW427353) | DRUG | - |
Inclusion Criteria: * Overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain. * Body mass index in the range of = 19 kg/m2 to \<35 kg/m2. Exclusion Criteria: * Pregnant * Of childbearing potential or willing ...
Solabegron is an investigational small molecule being developed for overactive bladder and irritable bowel syndrome (IBS). It is in Phase 1 clinical development, with completed trials in these indications. The drug is not approved and remains under clinical investigation.
Solabegron is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for overactive bladder and irritable bowel syndrome.
Solabegron is in Phase 1 clinical development. It has completed three trials, including a Phase 2 study in overactive bladder and two Phase 1 studies. The drug is investigational and has not been approved by regulatory authorities.
Solabegron has completed three clinical trials: NCT00343486, a Phase 2 dose-ranging study in female patients with overactive bladder symptoms; NCT00401479, a Phase 1 study on gastrointestinal transit in healthy volunteers; and NCT00427596, a Phase 1 study on medication formulation and food effect.
Solabegron is also known as GW427353, as referenced in clinical trial records. This alternative name may appear in scientific literature and study documentation. Both names refer to the same investigational drug being developed by GSK plc.